UHID / IP NO	40008443 (16851)	<b>RISNo./Status :</b>	4017444/ Provisional
Patient Name :	Mrs. MANJU SHARMA	Age/Gender :	57 Y/F
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:28AM/ OPSCR23- 24/9338	Scan Date :	
<b>Report Date :</b>	15/12/2023 10:29AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

## USG REPORT - ABDOMEN AND PELVIS

## LIVER:

Is normal in size and shows diffuse increased echotexture.

A simple cyst of size approx. 10x15mm seen in left lobe. No intra hepatic biliary radical dilatation seen.

### GALL BLADDER:

Adequately distended with no obvious wall thickening/pericholecystic fat stranding/fluid. No obvious calculus/polyp/mass seen within.

### **PANCREAS:**

Appears normal in size and shows uniform echo texture. The pancreatic duct is normal. No calcifications are seen.

### **SPLEEN:**

Appears normal in size and it shows uniform echo texture.

### **RIGHT KIDNEY:**

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

### LEFT KIDNEY:

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

### **URINARY BLADDER:**

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen.

### **UTERUS:**

Post-menopausal status.

Endometrial thickness measures ~ 3.5mm.

UHID / IP NO	40008443 (16851)	<b>RISNo./Status :</b>	4017444/ Provisional
Patient Name :	Mrs. MANJU SHARMA	Age/Gender :	57 Y/F
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:28AM/ OPSCR23- 24/9338	Scan Date :	
<b>Report Date :</b>	15/12/2023 10:29AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

## **ADNEXAE:**

No adnexal mass seen.

No focal fluid collections seen.

**IMPRESSION:** 

Grade-I fatty liver.

Simple hepatic cyst.

Rem Jadiys

DR. RENU JADIYA Consultant – Radiology MBBS, DNB

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40008443 (16851)	<b>RISNo./Status :</b>	4017444/
Patient Name :	Mrs. MANJU SHARMA	Age/Gender :	57 Y/F
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:28AM/ OPSCR23- 24/9338	Scan Date :	
<b>Report Date :</b>	15/12/2023 12:19PM	Company Name:	Provisional

### **REFERRAL REASON: HEALTH CHECKUP**

#### **2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER**

#### **M MODE DIMENSIONS: -**

Normal Normal								
IVSD	9.6	6-12mm			LVIDS	24.6	20-40mm	
LVIDD	36.1		32-	57mm		LVPWS	16.9	mm
LVPWD	11.1		6-1	2mm		AO	32.3	19-37mm
IVSS	16.9		J	mm		LA	29.4	19-40mm
LVEF	60-62		>	55%		RA	-	mm
	DOPPLEH	R MEA	SUREM	IENTS &	& CALC	ULATIONS	:	
STRUCTURE	MORPHOLOGY		VELOC	CITY (m	/s)	GRADIENT		REGURGITATION
				ì	·	(mml	H <u>g)</u>	
MITRAL	NORMAL	Е	0.79	e'	0.07	-		NIL
VALVE		Α	0.97	E/e'	11.2			
TRICUSPID	NORMAL		Е	0.	59	-		NIL
VALVE			A	0	51	-		
		A 0.51						
AORTIC	NORMAL	1.23			-		NIL	
VALVE								
PULMONARY	NORMAL		(	).77				NIL
VALVE						-		

#### **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- GRADE I LV DIASTOLIC DYSFUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - GRADE I LV DIASTOLIC DYSFUNCTION, NORMAL BI VENTRICULAR SYSTOLIC FUNCTION

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA MBBS, PGDCC, FIAE CONSULTANT & INCHARGE EMERGENCY, PREVENTIVE CARDIOLOGY AND WELLNESS CENTRE

Patient Name UHID	Mrs. MANJU SHARMA 40008443		Lab Col	No lection Date	4017444 15/12/2023 8:43A	М
Age/Gender IP/OP Location	57 Yrs/Female O-OPD			eiving Date oort Date	15/12/2023 8:49A 15/12/2023 2:55PI	
Referred By	EHS CONSULTANT		Rep	oort Status	Final	
Mobile No.	9772157693					
			BIOCHEMISTRY			
Test Name		Result	Unit	Biologi	cal Ref. Range	
BLOOD GLUCOSE (F	ASTING)					Sample: Fl. Plasm
BLOOD GLUCOSE (FA	ASTING)	94.9	mg/dl	74 - 106		
Method: Hexokinase Interpretation:-Di various diseases.	e assay. Lagnosis and monitoring of	treatment in d	liabetes mellitus and	evaluation of ca	arbohydrate metabolis	m in
BLOOD GLUCOSE (P	<u>P)</u>					Sample: PLASM
BLOOD GLUCOSE (PI	P)	104.5	mg/dl		ic: - < 140 mg/dl c: - 140-199 mg/dl	
Mathad, Havakinaa				Diabetic: - >=	200 mg/dl	
various diseases.	lagnosis and monitoring of	treatment in c	liabetes mellitus anc		-	
Interpretation:-Di various diseases. LFT (LIVER FUNCTIO	lagnosis and monitoring of			d evaluation of ca	-	
Interpretation:-Di various diseases. L <mark>FT (LIVER FUNCTIO</mark> BILIRUBIN TOTAL	agnosis and monitoring of <u>N TEST)</u>	0.52	mg/dl	i evaluation of c. 0.00-1.20	-	
Interpretation:-Di various diseases. LFT (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44	mg/dl mg/dl	d evaluation of ca 0.00 - 1.20 0.20 - 1.00	-	m in Sample: Serur
Interpretation:-Di various diseases. LFT (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44 0.08	mg/dl mg/dl mg/dl	d evaluation of co 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40	-	
Interpretation:-Di various diseases. BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT SGOT	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44 0.08 23.1	mg/dl mg/dl mg/dl U/L	d evaluation of ca 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40 0.0 - 40.0	-	
Interpretation:-Di various diseases. LET (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT SGOT SGPT	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44 0.08	mg/dl mg/dl mg/dl U/L U/L	d evaluation of co 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40	-	
Interpretation:-Di various diseases. EFT (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT SGOT SGPT TOTAL PROTEIN	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44 0.08 23.1 24.2	mg/dl mg/dl mg/dl U/L U/L g/dl	d evaluation of ca 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40 0.0 - 40.0 0.0 - 40.0	-	
Interpretation:-Di various diseases. IFT (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT SGOT SGPT TOTAL PROTEIN ALBUMIN	agnosis and monitoring of <u>N TEST)</u>	0.52 0.44 0.08 23.1 24.2 7.4	mg/dl mg/dl mg/dl U/L U/L	e evaluation of ca 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40 0.0 - 40.0 0.0 - 40.0 6.6 - 8.7	-	
Interpretation:-Di various diseases. LFT (LIVER FUNCTIO BILIRUBIN TOTAL	agnosis and monitoring of <u>N TEST)</u> -	0.52 0.44 0.08 23.1 24.2 7.4 4.4	mg/dl mg/dl mg/dl U/L U/L g/dl	d evaluation of ca 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40 0.0 - 40.0 0.0 - 40.0 6.6 - 8.7 3.5 - 5.2	-	
Interpretation:-Di various diseases. EFT (LIVER FUNCTIO BILIRUBIN TOTAL BILIRUBIN INDIRECT BILIRUBIN DIRECT SGOT SGPT TOTAL PROTEIN ALBUMIN GLOBULIN	agnosis and monitoring of <u>N TEST)</u> -	0.52 0.44 0.08 23.1 24.2 7.4 4.4 3.0	mg/dl mg/dl mg/dl U/L U/L g/dl g/dl	e evaluation of ca 0.00 - 1.20 0.20 - 1.00 0.00 - 0.40 0.0 - 40.0 0.0 - 40.0 6.6 - 8.7 3.5 - 5.2 1.8 - 3.6	-	

**RESULT ENTERED BY : SUNIL EHS** 



#### Dr. ABHINAY VERMA

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### BIOCHEMISTRY

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder. ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GCTP-GAMMA GLUTAWIL TRANSPEPTIDASE :- Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	211		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	46.8		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	119.5		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	41	mg/dl	10 - 50
TRIGLYCERIDES	203.9		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	4.5	%	

#### **RESULT ENTERED BY : SUNIL EHS**

AlbinayVen

#### Dr. ABHINAY VERMA

Patient Name UHID	Mrs. MANJU SHARMA 40008443	Lab No Collection Date	4017444 15/12/2023 8:43AM
Age/Gender	57 Yrs/Female O-OPD	Receiving Date Report Date	15/12/2023 8:49AM
IP/OP Location Referred By	EHS CONSULTANT	Report Status	15/12/2023 2:55PM Final
Mobile No.	9772157693		

#### BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders.

HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method. Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay. Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are

Synthesized in the liver. CHOLESTEROL VLDL :- Method: VLDL Calculative

Interpretation:-High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	20.10	mg/dl	16.60 - 48.50
BUN	9.4	mg/dl	6 - 20
CREATININE	0.58	mg/dl	0.50 - 0.90
SODIUM	143.9	mmol/L	136 - 145
POTASSIUM	4.26	mmol/L	3.50 - 5.50
CHLORIDE	102.5	mmol/L	98 - 107
URIC ACID	3.0	mg/dl	2.6 - 6.0
CALCIUM	9.30	mg/dl	8.60 - 10.30

**RESULT ENTERED BY : SUNIL EHS** 



**Dr. ABHINAY VERMA** 

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease. URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

**POTASSIUM** :- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure. **CHLORIDE - SERUM** :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usuallyassociated with hypercalcemia. Increased serum calcium levels may also beobserved in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

**RESULT ENTERED BY : SUNIL EHS** 

Patient Name UHID	Mrs. MANJU SHARMA 40008443	Lab No Collection Date	4017444 15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

### **BLOOD BANK INVESTIGATION**

Test Name	Result	Unit	Biological Ref. Range

**BLOOD GROUPING** 

"O" Rh Positive

Note :

Both forward and reverse grouping performed.
Test conducted on EDTA whole blood.

**RESULT ENTERED BY : SUNIL EHS** 



Dr. ABHINAY VERMA

Patient Name UHID	Mrs. MANJU SHARMA 40008443	Lab No Collection Date	4017444 15/12/2023 8:43AM	
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM	
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM	
Referred By	EHS CONSULTANT	Report Status	Final	
Mobile No.	9772157693			

### **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	25	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
РН	5.0 L		5.5 - 7.0	
SPECIFIC GRAVITY	1.005		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	2-3	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

**RESULT ENTERED BY : SUNIL EHS** 

AlbunayVana

Dr. ABHINAY VERMA

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### **CLINICAL PATHOLOGY**

BACTERIA	NIL	NIL
OHTERS	NIL	NIL

Methodology:-

Methodology:-Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY : SUNIL EHS** 

AldrineyVen

**Dr. ABHINAY VERMA** 

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Rai	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.8	g/dl	12.0 - 15.0	
PACKED CELL VOLUME(PCV)	40.4	%	36.0 - 46.0	
MCV	86.9	fl	82 - 92	
MCH	27.5	pg	27 - 32	
MCHC	31.7 L	g/dl	32 - 36	
RBC COUNT	4.65	millions/cu.mm	3.80 - 4.80	
TLC (TOTAL WBC COUNT)	7.34	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	58.0	%	40 - 80	
LYMPHOCYTE	31.1	%	20 - 40	
EOSINOPHILS	5.7	%	1 - 6	
MONOCYTES	4.5	%	2 - 10	
BASOPHIL	0.7 L	%	1 - 2	
PLATELET COUNT	2.44	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia. MCV :- Method:- Calculation bysysmex. MCH :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry

LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry

EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry

BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)

35 H

mm/1st hr 0 - 15

**RESULT ENTERED BY : SUNIL EHS** 

AlerinaryVan

#### **Dr. ABHINAY VERMA**

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

**RESULT ENTERED BY : SUNIL EHS** 

Patient Name	Mrs. MANJU SHARMA	Lab No	4017444
UHID	40008443	Collection Date	15/12/2023 8:43AM
Age/Gender	57 Yrs/Female	<b>Receiving Date</b>	15/12/2023 8:49AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:55PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		
	V Devi		

X Ray

Unit

Test Name

Result

**Biological Ref. Range** 

## X-RAY - CHEST PA VIEW

## **OBSERVATION:**

The trachea is central.

The mediastinal and cardiac silhouette are normal.

Cardiothoracic ratio is normal.

Cardiophrenic and costophrenic angles are normal.

Both hila are normal.

The lung fields are clear.

Bones of the thoracic cage are normal.

\*\*End Of Report\*\*

**RESULT ENTERED BY : SUNIL EHS** 

Rundad

Dr. RENU JADIYA MBBS, DNB RADIOLOGIST

Patient Name	Mrs. MANJU SHARMA	Lab No	587438	
UHID	331344	Collection Date	15/12/2023 10:33AM	
Age/Gender	57 Yrs/Female	Receiving Date	15/12/2023 10:35AM	MC-2561
IP/OP Location	O-OPD	Report Date	15/12/2023 12:49PM	
Referred By	Dr. EHCC Consultant	Report Status	Final	W0-2501
Mobile No.	9773349797			

#### BIOCHEMISTRY

Test Name <u>THYROID T3 T4 TSH</u>	Result	Unit	Biological Ref. Range	Sample: Serum
ТЗ	0.977	ng/mL	0.800 - 2.000	
Τ4	6.44	ug/dl	5.10 - 14.10	
TSH	1.17	μIU/mL	0.27 - 5.20	

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater oppositechanges in the TSH levels.

\*\*End Of Report\*\*

**RESULT ENTERED BY : Mr. Ravi** 

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS [MD] PATHOLOGY



Dr. ASHISH SHARMA CONSULTANT & INCHARGE PATHOLOGY MBBS|MD| PATHOLOGY

Page: 1 Of 1

Patient Name	Mrs. MANJU SHARMA	Lab No	587438	ATTINT ST
UHID Age/Gender	331344 57 Yrs/Female	Collection Date Receiving Date	15/12/2023 10:33AM 15/12/2023 10:35AM	HILD HILL
IP/OP Location	O-OPD	Report Date	15/12/2023 11:45AM	MC-2561
Referred By	Dr. EHCC Consultant	Report Status	Final	
Mobile No.	9773349797			
BIOCHEMISTRY				

Test Name	Result	Unit	Biological Ref. Range
			Sample: WHOLE BLOOD EDTA
HBA1C	5.6	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients
			< 7 % Excellent Control
			7 - 8 % Good Control
			> 8 % Poor Control

Method : - High - performance liquid chromatography HPLC Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

\*\*End Of Report\*\*

**RESULT ENTERED BY : Mr. MAHENDRA KUMAR** 

Dr. SURENDRA SINGH **CONSULTANT & HOD** MBBS | MD | PATHOLOGY



Dr. ASHISH SHARMA **CONSULTANT & INCHARGE PATHOLOGY** MBBS | MD | PATHOLOGY

UHID / IP NO	40008443 (16851)	<b>RISNo./Status :</b>	4017444/
Patient Name :	Mrs. MANJU SHARMA	Age/Gender :	57 Y/F
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:28AM/ OPSCR23- 24/9338	Scan Date :	
<b>Report Date :</b>	15/12/2023 10:25AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

**USG REPORT - BOTH BREASTS** 

## **RIGHT BREAST:**

### Parenchyma

Skin Thickness normal

Sub cutaneous fat normal.

No ductal Dilatation.

No focal lesion seen.

Fibroglandular echogenicity normal.

Nipple areolar complex normal.

### Retromammary

Retromammary area appeared normal

**Axillary Tail** 

Axillary Tail: Normal.

**Axillary Nodes** 

Few small volume lymphnodes with intact fatty hilum seen, largest 4mm in short axis.

### LEFT BREAST:

### Parenchyma

Skin Thickness normal.

Sub cutaneous fat normal.

No ductal Dilatation.

No focal lesion seen.

Fibroglandular echogenicity normal.

Nipple areolar complex normal.

### Retromammary

UHID / IP NO	40008443 (16851)	<b>RISNo./Status :</b>	4017444/
Patient Name :	Mrs. MANJU SHARMA	Age/Gender :	57 Y/F
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:28AM/ OPSCR23- 24/9338	Scan Date :	
<b>Report Date :</b>	15/12/2023 10:25AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

Retromammary area appeared normal

## Axillary Tail

Axillary Tail: Normal.

## **Axillary Nodes**

Few small volume lymphnodes with intact fatty hilum seen, largest 3.5mm in short axis.

### **IMPRESSION:**

- Right breast parenchyma is normal.
- Left breast parenchyma is normal.
- Radiologically benign appearing bilateral axillary lymphnodes.
  - Suggested clinical correlation for further evaluation.

Reme Jadiys

DR. RENU JADIYA Consultant – Radiology MBBS, DNB